152P Efficacy and safety of relacorilant + nab-paclitaxel in patients aged ≥65 years with platinum-resistant ovarian cancer (PROC) in the phase III ROSELLA study (GOG-3073, ENGOT-ov72, APGOT-Ov10)

ESMO Open · Published 2026-07-01 · DOI 10.1016/j.esmoop.2026.108199

Free full text

Authors (20)

A. Olawaiye, F. Derquin, N. Taylor, J-W. Kim, M. Scaranti, G. Valabrega, M.J. Messing, C.I. Diakos, G. Huygh, L. Willmott, A. Oaknin, E. Munro, L. Gladieff, C. Andreetta, R.L. Póka, S. Khalique, Y. Wang, S. Pai, S. Derio, D. Lorusso

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Olawaiye, A., Derquin, F., Taylor, N., et al. (2026). 152P Efficacy and safety of relacorilant + nab-paclitaxel in patients aged ≥65 years with platinum-resistant ovarian cancer (PROC) in the phase III ROSELLA study (GOG-3073, ENGOT-ov72, APGOT-Ov10). ESMO Open. https://doi.org/10.1016/j.esmoop.2026.108199

Related articles